BiotechTube

SBR759 + Sevelamer HCl + SBR759 + Sevelamer HCl

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy

Conditions

Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy

Trial Timeline

Jul 1, 2008 → —

NCT ID
NCT00704483

About SBR759 + Sevelamer HCl + SBR759 + Sevelamer HCl

SBR759 + Sevelamer HCl + SBR759 + Sevelamer HCl is a phase 2 stage product being developed by Novartis for Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy. The current trial status is completed. This product is registered under clinical trial identifier NCT00704483. Target conditions include Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy.

What happened to similar drugs?

2 of 15 similar drugs in Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy were approved

Approved (2) Terminated (0) Active (13)
✅Tenapanor + Sevelamer CarbonateArdelyxApproved
✅Ferric Citrate 1 gram Oral Tablet + Standard of care phosphate-lowering therapyAkebia TherapeuticsApproved
🔄KHK7791 + PlaceboKyowa KirinPhase 3
🔄KHK7791 + PlaceboKyowa KirinPhase 3
🔄KHK7791Kyowa KirinPhase 3
🔄KHK7791Kyowa KirinPhase 3
🔄SBR759A + SBR759A + SBR759A + SBR759A + SBR759ANovartisPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00704483Phase 2Completed

Competing Products

20 competing products in Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy

See all competitors
ProductCompanyStageHype Score
EOS789 + Placebo + RenvelaChugai PharmaceuticalPhase 1
29
DS-2330b PIB + Placebo + Sevelamer + DS-2330b TabletDaiichi SankyoPhase 1
29
ASP1585 + Placebo + Sevelamer hydrochlorideAstellas PharmaPhase 2
35
ASP1585Astellas PharmaPhase 2
35
the standard-dose group (4 g/day)Kyowa KirinPre-clinical
33
KHK7791 + PlacebpKyowa KirinPhase 2
35
KHK7791Kyowa KirinPhase 2
35
KHK7791 + PlaceboKyowa KirinPhase 3
40
the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)Kyowa KirinPre-clinical
33
KHK7791 + PlaceboKyowa KirinPhase 3
40
KHK7791Kyowa KirinPhase 3
40
KHK7791 + PlaceboKyowa KirinPhase 2
35
KHK7791Kyowa KirinPhase 3
40
SBR759A + SBR759A + SBR759A + SBR759A + SBR759ANovartisPhase 3
40
PA21Kissei PharmaceuticalPhase 3
40
Placebo + Sevelamer Carbonate (GZ419831)SanofiPhase 3
40
Placebo + Sevelamer carbonateSanofiPhase 2
35
Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tabletBayerPre-clinical
23
Lanthanum Carbonate (Fosrenol, BAY77-1931)BayerPre-clinical
23
Lanthanum Carbonate (BAY77-1931)BayerPhase 2
32